On October 18, 2022 Exelixis (Nasdaq: EXEL) reported that its third quarter 2022 financial results will be released on Tuesday, November 1, 2022 after the markets close (Press release, Exelixis, OCT 18, 2022, View Source [SID1234622121]). At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company’s website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call 888-338-9509 (domestic) or 412-902-4281 (international) and ask to be joined into the Exelixis conference call to participate by phone.

A telephone replay will be available until 8:00 p.m. ET on November 3, 2022. Access numbers for the telephone replay are: 877-344-7529 (domestic) and 412-317-0088 (international); the passcode is 6992264. A webcast replay will also be archived on www.exelixis.com for one year.

On October 18, 2022, Denovicon Therapeutics reported that its Founder & CEO, Scott Bembenek, presented on ‘An AI–Molecular Modeling Platform for Streamlining Small-Molecule Drug Discovery’ at the Biovia User Group Meeting 2022 (Press release, Denovicon Therapeutics, OCT 18, 2022, View Source [SID1234622115]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On October 18, 2022 Guangzhou Zhiyi Biotech reported that it was approved to start US Phase I trial of its live biopharmaceutical product to treat chemotherapy-induced diarrhea (CID) (Press release, Guangzhou Zhiyi Biotech, OCT 18, 2022, View Source [SID1234622113]). SK10, an inactivated Bacteroides fragilis-based LBP, has shown efficacy in CID models, according to Zhiyi. It is the first LBP product approved for CID trials globally. Zhiyi says the US approval is a milestone for the company, starting trials of an LBP product in the US and China. Earlier this year, Zhiyi raised $15 million in its B++ funding, bringing the total of three B rounds to $45 million.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On October 18, 2022 Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, reported that it will announce its financial results for the quarter ended September 30, 2022, on Tuesday, November 1, 2022 after the close of the market, and provide a corporate update (Press release, Aptose Biosciences, OCT 18, 2022, View Source [SID1234622110]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call & Webcast:

Date: Tuesday, November 1, 2022
Time: 5:00 PM ET
Audio Webcast Only: link
Q&A Participant Registration Link*: here

(https://register.vevent.com/register/BIc687e1f1cee54e22b3d29e917044b145)
*Please note the change in platform. Analysts interested in participating in the question-and-answer session will pre-register for the event from the participant registration link above to receive the dial-in numbers and a personal PIN, which are required to access the conference call. They also will have the option to take advantage of a new Call Me button and the system will automatically dial out to connect to the Q&A session.

The audio webcast can also be accessed through a link on the Investor Relations section of Aptose’s website here. A replay of the webcast will be available on the company’s website for 30 days.

The press release, the financial statements and the management’s discussion and analysis for the quarter ended September 30, 2022 will be available on SEDAR at www.sedar.com and EDGAR at www.sec.gov/edgar.shtml.

On October 18, 2022 Kureha Corporation reported that it has resolved at the meeting of the Board of Directors today to pay the following dividend to shareholders held in record as of September 30, 2022 (Press release, Kureha Corporation, OCT 18, 2022, View Source [SID1234622107]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

1. Details of dividend payment
2. Reasons

Kureha’s basic policy regarding dividend distribution is to pay a steady dividend to shareholders over a long period of time, while strengthening the company’s financial structure to sustain long-term growth and future business development. From this standpoint, Kureha has determined to pay 125 yen per share for the FY2022 interim dividend, which is consistent with its most recent forecast.